These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21707476)

  • 1. Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors.
    Carriero MV; Franco P; Votta G; Longanesi-Cattani I; Vento MT; Masucci MT; Mancini A; Caputi M; Iaccarino I; Stoppelli MP
    Curr Drug Targets; 2011 Nov; 12(12):1761-71. PubMed ID: 21707476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure, function and antagonists of urokinase-type plasminogen activator.
    Vincenza Carriero M; Franco P; Vocca I; Alfano D; Longanesi-Cattani I; Bifulco K; Mancini A; Caputi M; Stoppelli MP
    Front Biosci (Landmark Ed); 2009 Jan; 14(10):3782-94. PubMed ID: 19273310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
    Carriero MV; Stoppelli MP
    Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM; Strickland S
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation and role of urokinase plasminogen activator in vascular remodelling.
    Tkachuk V; Stepanova V; Little PJ; Bobik A
    Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase.
    Liu J; Chakraborty C; Graham CH; Barbin YP; Dixon SJ; Lala PK
    Exp Cell Res; 2003 May; 286(1):138-51. PubMed ID: 12729802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domain-dependent action of urokinase on smooth muscle cell responses.
    Tanski WJ; Fegley AJ; Roztocil E; Davies MG
    J Vasc Surg; 2004 Jan; 39(1):214-22. PubMed ID: 14718842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).
    Takada Y
    J Biomed Biotechnol; 2012; 2012():136302. PubMed ID: 23125522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
    Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
    Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for therapeutic intervention of uPA/uPAR system.
    Ngo JC; Jiang L; Lin Z; Yuan C; Chen Z; Zhang X; Yu H; Wang J; Lin L; Huang M
    Curr Drug Targets; 2011 Nov; 12(12):1729-43. PubMed ID: 21707478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
    Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
    J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.
    Poliakov A; Tkachuk V; Ovchinnikova T; Potapenko N; Bagryantsev S; Stepanova V
    Biochem J; 2001 May; 355(Pt 3):639-45. PubMed ID: 11311125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The urokinase plasminogen activator: an interesting way to improve myoblast migration following their transplantation.
    El Fahime E; Mills P; Lafreniere JF; Torrente Y; Tremblay JP
    Exp Cell Res; 2002 Nov; 280(2):169-78. PubMed ID: 12413883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase plasminogen activator system as a potential target for cancer therapy.
    Mekkawy AH; Morris DL; Pourgholami MH
    Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.